Menu

Wolbachia-infected Mosquitoes Released in Florida

The bacterium causes eggs to die, and spreading treated insects is expected to curb Aedes aegypti populations.

Apr 19, 2017
Kerry Grens

FLICKR, TUPINUMBAH

Kentucky-based MosquitoMate released 20,000 male Aedes aegypti this week (April 18) in a field trial in the Florida Keys, testing the insects’ abilities to tamp down the local mosquito population. These male mosquitoes were treated with the bacterium Wolbachia, which causes eggs to perish when infected males mate with uninfected females.

“We’re looking at these sterile insect techniques because our conventional mosquito control methods are costly and labor-intensive,” Andrea Leal, executive director of the Florida Keys Mosquito Control District, told the Associated Press.

Wolbachia-laced mosquitoes have been deployed in several sites around the globe, including Colombia, Brazil, and Vietnam. MosquitoMate’s insects were previously tested in California.

According to the company’s website, 40,000 mosquitoes will be released each week for 12 weeks.

Earlier this year, scientists reported details of how Wolbachia infections cause sterility in mosquitoes, through the expression of two genes that interfere with reproduction in hosts.

Plans to test another emerging approach to shrinking mosquito numbers, via genetically modified (GM) insects, stalled in Florida. The company behind the proposed field test, Oxitec, has released GM mosquitoes in Brazil, Panama, and elsewhere and reported reduced mosquito counts.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.